EUCTR2014-003731-20-IT进行中（未招募）1 期
A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer - NA
OVARTIS FARMA S.P.A.0 个研究点目标入组 64 人开始时间: 2015年5月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Advanced metastatic and/or unresectable NSCLC
- •Measurable disease as determined by RECIST version 1.1
- •ECOG performance =2
- •Patients in Group 1: confirmed T790M EGFR mutation
- •Patients in Group 2: confirmed c-MET positive
- •Other inclusion criteria may apply as per protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •For Group 1: Patients who have received more than one prior line of EGFR TKI therapy
- •For Group 2: Previous treatment with a c-MET inhibitor or HGFtargeting therapy
- •Prior treatment with PD1/PD-L1 targeting therapies
- •Subjects who require emergent use of systemic steroids, emergent surgery and/or radiotherapy
- •Patients with interstitial lung disease
- •Patients with any active or history of autoimmune disease
- •Other exclusion criteria may apply as per protocol
研究者
相似试验
进行中（未招募）
1 期
Study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancerEGFR mutated non-small cell lung cancer and EGFR wild-type non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864EUCTR2014-003731-20-NLovartis Pharma Services AG100
进行中（未招募）
1 期
Study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancerEGFR mutated non-small cell lung cancer and EGFR wild-type non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864EUCTR2014-003731-20-DEovartis Pharma Services AG100
已完成
2 期
A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer (CEGF816X2201C)non-small cell lung cancer (NSCLC)1000628810029107lung cancerNL-OMON44688ovartis Pharma B.V.5
进行中（未招募）
1 期
Study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancerEGFR mutated non-small cell lung cancer and cMet positive non-small cell lung cancerMedDRA version: 17.1Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864EUCTR2014-003731-20-ESovartis Farmacéutica, S.A.100
进行中（未招募）
1 期
An interventional study of oral EGF816 in adult patients with EGFRmut solid malignanciesSolid tumorsMedDRA version: 17.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2013-004482-14-ESovartis Farmacéutica, S.A.211